Amgen filed a lawsuit in US district court of Dalaware against sanofi and Regeneron pharmaceuticals . They allegedly infringed US patent rights with patent numbers 8563698,8829165,8859741. These patents are owned by Amgen which describe and claim monoclonal antibodies to pro-protein convertase subtilisin/kexin type 9 {PCSK9}. With this lawsuit Agmen wants injunction to prevent infringing sale of Alirocumab,a monoclonal antibody targeting pcsk9 from Regeneron pharmaceuticals as they recently announced seeking regulatory approval for marketing alirocumab in US
Showing posts with label pcsk9. Show all posts
Showing posts with label pcsk9. Show all posts
Evolocumab,a PCSK9 inhibitor filed with US FDA for treatment of high cholesterol
PCSK9 inhibitor,Evolocumab is highly efficient in patients with elevated cholesterol or stations, hetero zygous familial hypercholesterolemia(HeFH), homo zygous familial hyper-cholesterolemia (HoFH),a genetic disorder.
Amgen,the developer of the Evolocumab has filed for US FDA approval .The data filed contains information from ten phase 3 clinical trials performed on 6,800 patients , including more than 4500 patients with high cholesterol.
PCSK9 , is a protein that reduces the Liver ability to remove harmful cholesterol from the blood.
Amgen (AMGN) is an American bio pharmaceutical company headquarters in Thousand Oaks , California.
Amgen,the developer of the Evolocumab has filed for US FDA approval .The data filed contains information from ten phase 3 clinical trials performed on 6,800 patients , including more than 4500 patients with high cholesterol.
PCSK9 , is a protein that reduces the Liver ability to remove harmful cholesterol from the blood.
Amgen (AMGN) is an American bio pharmaceutical company headquarters in Thousand Oaks , California.
Location:
Thousand Oaks, CA, USA
Labels:
Amgen,
bad cholesterol,
california,
elevated cholesterol,
evolocumab,
harmful cholesterol in blood,
HeFH,
HoFH,
hyper cholesterolemia,
liver,
PCKS9 inhibitor,
pcsk9,
us fda
Subscribe to:
Posts (Atom)